How Effective Is Mounjaro and Wegovy for Weight Loss?

Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist — meaning it acts on two appetite-related hormonal pathways rather than one. Wegovy contains semaglutide, a GLP-1 receptor agonist. Both medicines are thought to help reduce appetite and increase feelings of fullness, and Mounjaro's dual mechanism is a key area of ongoing scientific interest. You can read more about the underlying science in our guide to how Mounjaro works.

Important context around effectiveness

When considering how effective weight loss injections are, it helps to keep a few things in mind:

• Results vary between individuals. Clinical trials report averages across large groups; any one person's experience may differ substantially from those figures.
• Lifestyle factors matter. These medicines are intended to be used alongside changes to diet and activity levels, not as a standalone solution.
• Dose and duration play a role. Both medicines are typically started at a low dose and adjusted over time by the prescriber — the body's response often changes as the dose changes.
• They are not insulin. If you have heard these medicines described in that context, our page on whether Mounjaro is insulin clarifies the distinction.

How do Mounjaro and Wegovy compare?

Both are effective prescription medicines for weight management, but they are not identical. Tirzepatide's dual-receptor action distinguishes it mechanically from semaglutide's single GLP-1 action. Whether one is more appropriate than the other for a given person is a clinical decision that belongs entirely with their prescriber — it is not something a tracking app, or general content, should steer. For a factual, side-by-side look, see our page on how effective Wegovy is, and for context on how Wegovy relates to other semaglutide medicines, our page on whether Wegovy and Ozempic are the same may be useful. According to NHS guidance, both medicines are prescription-only and suitable only for people who meet specific clinical criteria — suitability is always decided by a qualified prescriber.

Population-level data tells you what happened on average in a trial; your own data tells you what is actually happening for you. That gap is where GLP Trackr is most useful.

The app's weight and body tracking feature lets you log your weight regularly and watch your trend line develop over weeks, rather than fixating on day-to-day fluctuations that can be misleading. Charts and a weekly transformation view help you see genuine progress that the scale alone might obscure on any given morning.

Alongside weight, the daily check-in captures mood, energy, sleep, and food-noise levels — factors that often shift as the medicine takes effect and that are worth monitoring over time. When you bring these records to a prescriber appointment, you are having a much more informed conversation about how the medicine is working for you specifically, rather than relying on memory.

If you are curious about what is driving your results, the app's insights and correlations tools can surface patterns in your own data — for example, whether higher protein intake or better sleep tends to align with better progress weeks.

GLP Trackr helps you record the full picture so you can discuss it with your prescriber — it is not a substitute for their clinical guidance, and any questions about whether the medicine is working as expected, or whether your dose should be reviewed, should always go to your healthcare professional.

Ready to start understanding your own journey rather than just the averages? Download GLP Trackr on the App Store or Google Play and explore it free for 7 days — no commitment needed.